PharmacoEconomics

Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age?
pp. 107-108(2)
Authors: Drummond, Michael; Sculpher, Mark

Sociodemographic Differences in Quality of Life in Rheumatoid Arthritis
pp. 109-121(13)
Authors: Groessl, Erik J.; Ganiats, Theodore G.; Sarkin, Andrew J.

Differential Effects of Atypical versus Typical Antipsychotic Medication on Earnings of Schizophrenia Patients: Estimates from a Prospective Naturalistic Study
pp. 123-139(17)
Authors: Salkever, David; Slade, Eric; Karakus, Mustafa

Combination Vaccine Against Invasive Meningococcal B and Pneumococcal Infections: Potential Epidemiological and Economic Impact in The Netherlands
pp. 141-153(13)
Authors: Bos, Jasper M.; Rümke, Hans C.; Welte, Robert; Spanjaard, Lodewijk; Loek van Alphen,; Postma, Maarten J.

A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease
pp. 155-169(15)
Authors: Lamotte, Mark; Annemans, Lieven; Evers, Thomas; Kubin, Maria

The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia
pp. 171-191(21)
Authors: DiSantostefano, Rachael L.; Biddle, Andrea K.; Lavelle, John P.

Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries: France, Italy, Germany and the UK
pp. 193-205(13)
Authors: Lafuma, Antoine; Brézin, Antoine; Lopatriello, Stefania; Hieke, Klaus; Hutchinson, Julia; Mimaud, Viviane; Berdeaux, Gilles

How Much is the Cost of Visual Impairment: Caveat Emptor
pp. 207-209(3)
Authors: Meads, Catherine; Hyde, Chris

How Much is the Cost of Visual Impairment: the Author's Reply
pp. 210-210(1)
Author: Lafuma, Antoine